BELLUS Health Inc (BLU.CA)

CA07987C2040 - Common Stock

19.48  -0.02 (-0.1%)

Fundamental Rating

3

BLU gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 25 industry peers in the Biotechnology industry. The financial health of BLU is average, but there are quite some concerns on its profitability. BLU is quite expensive at the moment. It does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year BLU has reported negative net income.
BLU had a negative operating cash flow in the past year.
In the past 5 years BLU always reported negative net income.
In the past 5 years BLU always reported negative operating cash flow.

1.2 Ratios

The profitability ratios for BLU are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

BLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLU has been increased compared to 1 year ago.
The number of shares outstanding for BLU has been increased compared to 5 years ago.
Compared to 1 year ago, BLU has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 102.13 indicates that BLU is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 102.13, BLU belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
BLU has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
BLU has a Debt to Equity ratio of 0.00. This is in the better half of the industry: BLU outperforms 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 102.13
ROIC/WACCN/A
WACC7.86%

2.3 Liquidity

BLU has a Current Ratio of 33.42. This indicates that BLU is financially healthy and has no problem in meeting its short term obligations.
BLU has a Current ratio of 33.42. This is amongst the best in the industry. BLU outperforms 100.00% of its industry peers.
BLU has a Quick Ratio of 33.42. This indicates that BLU is financially healthy and has no problem in meeting its short term obligations.
BLU has a better Quick ratio (33.42) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 33.42
Quick Ratio 33.42

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.00% over the past year.
The Revenue has decreased by -6.25% in the past year.
BLU shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -34.23% yearly.
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-53.85%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Revenue growth Q2Q-25%

3.2 Future

Based on estimates for the next years, BLU will show a very strong growth in Earnings Per Share. The EPS will grow by 35.40% on average per year.
The Revenue is expected to grow by 654.86% on average over the next years. This is a very strong growth
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLU. In the last year negative earnings were reported.
Also next year BLU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as BLU's earnings are expected to decrease with -9.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%

0

5. Dividend

5.1 Amount

BLU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BELLUS Health Inc

TSX:BLU (6/29/2023, 6:00:00 PM)

19.48

-0.02 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.47B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 33.42
Quick Ratio 33.42
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-27.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y